Last reviewed · How we verify
IMGN632
At a glance
| Generic name | IMGN632 |
|---|---|
| Also known as | CD123-targeted ADC |
| Sponsor | AbbVie |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms (PHASE1)
- IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia (PHASE1, PHASE2)
- Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN (PHASE1, PHASE2)
- A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMGN632 CI brief — competitive landscape report
- IMGN632 updates RSS · CI watch RSS
- AbbVie portfolio CI